Table 5.
Association Between HDL Variables and Subspecies and Risk of T2D in 2390 Men and 2438 Women for Parameters With Significant Interaction With Sex
| Large HDL | Small HDL | H5P | H6P | |
|---|---|---|---|---|
| Men | ||||
| Events | 165 | 165 | 165 | 165 |
| Model 1 | 0.73 (0.62–0.85)*** | 1.09 (0.93–1.30) | 0.89 (0.75–1.05) | 0.80 (0.67–0.94)** |
| Model 2 | 0.69 (0.59–0.80)*** | 1.14 (0.96–1.35) | 0.89 (0.75–1.05) | 0.75 (0.64–0.89)** |
| Model 3 | 0.70 (0.60–0.82)*** | 1.12 (0.953–1.33) | 0.90 (0.77–1.06) | 0.77 (0.65–0.91)** |
| Model 4 | 0.87 (0.74–1.06) | 1.05 (0.88–1.24) | 0.98 (0.83–1.17) | 0.94 (0.78–1.13) |
| Model 5a | 0.97 (0.81–1.15) | 1.17 (0.99–1.38) | 0.93 (0.79–1.10) | 1.01 (0.84–1.23) |
| Model 5b | 0.98 (0.81–1.17) | 1.03 (0.87–1.23) | 1.01 (0.85–1.20) | 1.02 (0.84–1.23) |
| Model 6a | 1.09 (0.90–1.32) | 1.06 (0.86–1.31) | 0.98 (0.82–1.17) | 1.05 (0.86–1.28) |
| Model 6b | 1.04 (0.85–1.27) | 0.99 (0.83–1.18) | 1.03 (0.86–1.23) | 1.05 (0.86–1.28) |
| Women | ||||
| Events | 100 | 100 | 100 | 100 |
| Model 1 | 0.56 (0.47–0.67)*** | 1.45 (1.21–1.75)*** | 1.21 (1.01–1.45)* | 0.53 (0.44–0.63)*** |
| Model 2 | 0.56 (0.47–0.67)*** | 1.33 (1. 1–1.61)** | 1.17 (0.97–1.41) | 0.52 (0.43–0.63)*** |
| Model 3 | 0.57 (0.47–0.67)*** | 1.31 (1.09–1.59)** | 1.16 (0.96–1.39) | 0.53 (0.44–0.64)*** |
| Model 4 | 0.66 (0.54–0.82)*** | 1.19 (0.96–1.46) | 1.08 (0.89–1.31) | 0.63 (0.51–0.79)*** |
| Model 5a | 0.72 (0.58–0.89)** | 1.17 (0.95–1.43) | 1.04 (0.85–1.28) | 0.75 (0.60–0.94)* |
| Model 5b | 0.84 (0.67–1.05) | 1.09 (0.88–1.35) | 1.10 (0.89–1.35) | 0.75 (0.60–0.94)* |
| Model 6a | 0.77 (0.61–0.97)* | 1.10 (0.93–1.31) | 1.07 (0.87–1.31) | 0.77 (0.61–0.97)* |
| Model 6b | 0.88 (0.70–1.11) | 1.03 (0.82–1.28) | 1.10 (0.89–1.35) | 0.77 (0.62–0.97)* |
Hazard ratios (HRs) with 95% confidence intervals (CIs) s) were derived from Cox proportional hazard models. Significant associations are shown in bold.
Model 1: crude model; Model 2: model 1 + age, sex; Model 3: model 2 + family history of diabetes; Model 4: model 3 + smoking, alcohol consumption, body mass index, hypertension, high-sensitivity C-reactive protein, and use of lipid-lowering medication; Model 5a: model 4 + fasting plasma glucose; Model 5b: model 4 + homeostatic model assessment of insulin resistance; Model 6a: model 5a + low-density lipoprotein cholesterol (LDL-C), triglycerides; Model 6b: model 5b + LDL-C, triglycerides.
Abbreviations: H5P, high-density lipoprotein 5 particles (10.3 nm); H6P, high-density lipoprotein 6 particles (10.8 nm); HDL, high-density lipoprotein; T2D, type 2 diabetes.
*P < 0.05; **P < 0.01; ***P < 0.001.